Paul R. Edick - Dec 13, 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chairman & Chief Executive Officer, Director
Signature
/s/ Beth Hecht as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Dec 13, 2022
Transactions value $
$29,000
Form type
4
Date filed
12/14/2022, 03:11 PM
Previous filing
May 13, 2022
Next filing
Feb 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $29K +20K +1.33% $1.45 1.53M Dec 13, 2022 Direct
holding XERS Common Stock 33.4K Dec 13, 2022 By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Chairman & Chief Executive Officer